103628-48-4 Usage
Description
Different sources of media describe the Description of 103628-48-4 differently. You can refer to the following data:
1. Sumatriptan succinate is a synthetic drug belonging to a class of medications known as 5-hydroxytryptamine agonists (also called "triptans"), which is commonly used to treat cluster and migraine headaches with or without aura (warning signs occurring prior to the onset of a migraine). It is effective to relieve or eliminate the intensity of migraine and cluster headaches and accompanying symptoms including sensitivity to light or sound, nausea, and vomiting. However, it cannot help prevent future migraines/headaches or decrease the frequency of getting migraine and it is not recommended for other types of headache or for headache prevention.
It is believed that the pain of migraine headaches is induced by dilated blood vessels inside the head. Sumatriptan succinate relieves migraine headaches by affecting the serotonin in the brain, which results in constriction of blood vessels. Subcutaneous injection of this drug is more effective than other formulations.
2. Sumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a
new treatment for migraine. It is indicated for the acute relief of migraine and cluster
headache. Oral administration is reported to be free of substantial side effects. The
compound appears to be a significant advance over the use of ergotamine and other
agents in the treatment of migraine.
References
https://en.wikipedia.org/wiki/Sumatriptan
http://www.medicinenet.com/sumatriptan_succinate-injection/article.htm
http://bodyandhealth.canada.com/drug/getdrug/teva-sumatriptan-df
http://www.webmd.com/drugs/2/drug-7741/sumatriptan-oral/details
Chemical Properties
White Crystalline Powder
Originator
Glaxo (United Kingdom)
Uses
Different sources of media describe the Uses of 103628-48-4 differently. You can refer to the following data:
1. A serotonin 5HT1-receptor agonist
2. A selective 5-HT1 receptor agonist
3. Sumatriptan (succinate) is a serotonin 5-hydroxytryptamine 1 (5-HT1) receptor agonist with selective affinity for 5-HT1B and 5-HT1D receptors with IC50 values of 9.3 and 7.3 nM, respectively. It also has affinity for the 5-HT1F receptor (IC50 = 17.8 nM). Sumatriptan (succinate) has been shown to induce vasoconstriction of human middle meningeal arteries (EC50 = 89.9 nM) and reduce vascular inflammation associated with migraines.
4. Sumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).
Definition
ChEBI: A succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatm
nt of migraine with or without aura in adults.
Brand name
Imitrex (GlaxoSmithKline);Imigran.
World Health Organization (WHO)
Suprofen, a nonsteroidal anti-inflammatory agent, was introduced
in 1983 for use as an analgesic for the symptomatic relief of mild to moderate pain
and for primary dysmenorrhoea. By 1986 it had become evident that its use was
occasionally associated with flank pain sometimes accompanied by evidence of
decreased renal function. The Arthritis Advisory Committee of the United States
Food and Drug Administration met in December 1986 to review the situation and
decided against withdrawing suprofen from the market. However, in May 1987 the
Committee for Proprietary Medicinal Products of the European Community
recommended that all marketing authorizations should be suspended. The
manufacturer subsequently decided to suspend sale worldwide on the grounds
that sales had diminished to the point where the product was no longer
economically viable.
Biological Activity
Selective 5-HT 1 receptor agonist (K i values are 17, 27 and 100 nM at 5-HT 1D , 5-HT 1B and 5-HT 1A receptors respectively). Antimigraine agent.
Biochem/physiol Actions
Sumatriptan succinate is a 5-HT1 serotonin receptor agonist.
Check Digit Verification of cas no
The CAS Registry Mumber 103628-48-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,6,2 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 103628-48:
(8*1)+(7*0)+(6*3)+(5*6)+(4*2)+(3*8)+(2*4)+(1*8)=104
104 % 10 = 4
So 103628-48-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)/p-2
103628-48-4Relevant articles and documents
Isotope-Edited Infrared Spectroscopy for Efficient Discrimination between Pharmaceutical Salts and Cocrystals
Iwata, Kentaro,Karashima, Masatoshi,Ikeda, Yukihiro
, p. 2350 - 2358 (2017)
Isotope-edited infrared spectroscopy using carboxylic acids selectively labeled with 13C is proposed herein for the efficient discrimination of pharmaceutical salts and cocrystals, whereby proton-transfer probe vibrations are highlighted by isotope shifts. This new technique can accurately discriminate even a confusing salt from a cocrystal for the traditional method, highlighting the diagnostic peaks. In addition, the established technique also provided the OH in-plane bending vibrations corresponding to intermolecular hydrogen bonding at the carbonyl oxygens of the cocrystals. The technique will accelerate the discrimination, which is a critical process in cocrystal development.
SUMATRIPTAN CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS
-
Page 35-36, (2008/06/13)
The invention provides novel soluble sumatriptan crystalline forms that include polymorphs, salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these sumatriptan crystalline forms. Methods of using such compositions for the treatment or prevention of migraine headaches and related neurological disorders are also provided.
NOVEL CRYSTALLINE FORMS OF SUMATRIPTAN SUCCINATE
-
Page 3-4, (2008/06/13)
The present invention relates to novel crystalline forms of sumatriptan succinate, to processes for their preparation and to pharmaceutical compositions containing them.